PHIXFPhase Holographic Imaging PHI AB

About Phase Holographic Imaging PHI AB (PHIXF)

Phase Holographic Imaging PHI AB (PHIXF) is a N/A company headquartered in Lund, Sweden whose shares trade over-the-counter on the OTCQB tier.

Phase Holographic Imaging (PHI) is a medical technology company that develops and markets its non-invasive time-lapse imaging instruments for long-term quantitative analysis of living cells. The foundation of PHI’s current commercial HoloMonitor® products is Quantitative Phase Imaging (QPI) technology — an innovative approach to cell quality evaluation. QPI offers a detailed analysis of cell characteristics without harming the cells, avoiding the limitations of traditional measurement methods. PHI is actively focusing on business development to expand from pre-clinical research to the clinical market and the emerging regenerative medicine field. PHI envisions transforming live cell analysis and establishing QPI as a standard for cell quality control, making future cell therapies safe, affordable, and accessible for patients. PHI is based in Lund, Sweden, Boston, MA and Winston-Salem, NC.

Products and services

Phase Holographic Imaging (PHI) provides an innovative live cell analysis tool that lets researchers monitor living cells directly in their incubator. PHI has been active within the pre-clinical and biomedical cell research market, having established a global presence with their HoloMonitor® systems and their scientific validation in both academia and industry, primarily addressing cancer, stem cell and drug development research. PHI’s HoloMonitor technology, utilizing Quantitative Phase Imaging (QPI), ensures cells remain unaffected during analysis. Unlike conventional cell measurement methods that often require genetic manipulation or staining with toxic substances, QPI offers a non-invasive alternative that maintains the integrity of cell cultures. By enabling scientists to obtain better data without compromising cell health, HoloMonitor sets a new standard in drug development and basic medical research, aiming for more successful patient outcomes and reduced research expenses. PHI is expanding its reach into the clinical market and emerging regenerative medicine field, which presents significant growth opportunities. PHI aims to penetrate these markets in the future, where its non-invasive cell analysis solutions can offer critical cell quality control assessment. QPI technology has the potential to become a future standard method for cell quality control in regenerative medicine.

PHIXF key facts

Ticker symbol

PHIXF

Market tier

OTCQB

Headquarters

Lund, Sweden

Country of incorporation

SE

Year of incorporation

2004

Employees

14

Shares outstanding

26,192,925

Reporting standard

International Reporting: Spotlight Stock Market

Audit status

Audited

Fiscal year end

4/30

Latest filing

Quarterly Report (Jan 31, 2025)

Phase Holographic Imaging PHI AB leadership

• Ivan Jurkovic — CEO
• Lisa Bodily — Head of IR

Explore more: OTCQB stocks · OTC stocks starting with P